insights_auto
Why is GBT up ၅.၀၈%?
Dive Deeperchevron_right
GBT:EPA
Guerbet SA
၆.၄၁ €
arrow_upward
+၅.၀၈%(+၀.၃၁) 1D
နို ၆, GMT+၁ ၁၅:၅၆:၃၄ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GBT...
Open
၆.၁၂ €
High
၆.၄၂ €
Low
၆.၀၆ €
Mkt. cap
၈.၁၀ ကုဋေ
Avg. vol.
၁.၂၈ သောင်း
Volume
၂.၁၇ သောင်း
52-wk high
၁၈.၂၆ €
52-wk low
၅.၈၀ €
EPS
-၁၁.၀၅ €
Shares outstanding
၁.၂၆ ကုဋေ
No. of employees
၃ ထောင်
Open
၆.၁၂ €
High
၆.၄၂ €
Low
၆.၀၆ €
Mkt. cap
၈.၁၀ ကုဋေ
Avg. vol.
၁.၂၈ သောင်း
Volume
၂.၁၇ သောင်း
52-wk high
၁၈.၂၆ €
52-wk low
၅.၈၀ €
EPS
-၁၁.၀၅ €
Shares outstanding
၁.၂၆ ကုဋေ
No. of employees
၃ ထောင်
News stories
From web sources and news partners
FF News
·
ပြီးခဲ့သည့် ၂၇ မိနစ်
Gregg Jaclin on What Happens After the SEC Agrees to Take a Second Look
CNBC
·
ပြီးခဲ့သည့် ၁၃ မိနစ်
Opening Bell: November 6, 2026
Seeking Alpha
·
ပြီးခဲ့သည့် ၂၅ မိနစ်
Nasdaq, S&P 500 aim higher, attempting to move past tech selloff (COMP:IND:)
CNN
·
ပြီးခဲ့သည့် ၅ နာရီ
What sparked the stock market’s $2.5 trillion sell-off?
Profile
Guerbet is a France-based manufacturer of contrast agents used in medical imaging. The company was founded in 1926 by André Guerbet, the son of Marcel Guerbet who in 1901 discovered Lipiodol – the first iodinated X-ray contrast agent.
In 2017 Guerbet’s revenues were €807.1 million. It employs over 2,700 people worldwide and has manufacturing facilities in over 20 countries including France, Ireland, Canada, Macedonia, the United States and Brazil. The company’s headquarters is located in Villepinte, Seine-Saint-Denis.
In July 2015, Guerbet announced the takeover of a portion of Mallinckrodt's contrast media and application systems divisions. The acquisition was completed in November 2015.
In 2022, the United States Food and Drug Administration approved Guerbet Group's Elucirem, an MRI contrast agent. The product is produced at Guerbet's factory in Raleigh, North Carolina and at three of its French factories. Wikipedia
About Guerbet SA